Global Irritable Bowel Syndrome (IBS) Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
According to APO Research, The global Irritable Bowel Syndrome (IBS) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
This report presents an overview of global market for Irritable Bowel Syndrome (IBS), revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Irritable Bowel Syndrome (IBS), also provides the value of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome (IBS), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Irritable Bowel Syndrome (IBS) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Irritable Bowel Syndrome (IBS) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global @@@@ company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Descriptive company profiles of the major global players, including Bausch Health, Allergan, Takeda, Sucampo Pharmaceuticals (Mallinckrodt), Sebela Pharmaceuticals Inc and Astellas Pharmaceuticals, etc.
Irritable Bowel Syndrome (IBS) segment by Company
1. To analyze and research the global Irritable Bowel Syndrome (IBS) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Irritable Bowel Syndrome (IBS) key companies, revenue, market share, and recent developments.
3. To split the Irritable Bowel Syndrome (IBS) breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Irritable Bowel Syndrome (IBS) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Irritable Bowel Syndrome (IBS) significant trends, drivers, influence factors in global and regions.
6. To analyze Irritable Bowel Syndrome (IBS) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome (IBS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome (IBS) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome (IBS).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Irritable Bowel Syndrome (IBS) industry.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome (IBS) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Irritable Bowel Syndrome (IBS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Irritable Bowel Syndrome (IBS) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Chapter 9: Concluding Insights.
According to APO Research, The global Irritable Bowel Syndrome (IBS) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
This report presents an overview of global market for Irritable Bowel Syndrome (IBS), revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Irritable Bowel Syndrome (IBS), also provides the value of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome (IBS), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Irritable Bowel Syndrome (IBS) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Irritable Bowel Syndrome (IBS) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global @@@@ company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Descriptive company profiles of the major global players, including Bausch Health, Allergan, Takeda, Sucampo Pharmaceuticals (Mallinckrodt), Sebela Pharmaceuticals Inc and Astellas Pharmaceuticals, etc.
Irritable Bowel Syndrome (IBS) segment by Company
- Bausch Health
- Allergan
- Takeda
- Sucampo Pharmaceuticals (Mallinckrodt)
- Sebela Pharmaceuticals Inc
- Astellas Pharmaceuticals
- IBS-D Drug
- IBS-C Drug
- Others
- Women
- Men
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Irritable Bowel Syndrome (IBS) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Irritable Bowel Syndrome (IBS) key companies, revenue, market share, and recent developments.
3. To split the Irritable Bowel Syndrome (IBS) breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Irritable Bowel Syndrome (IBS) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Irritable Bowel Syndrome (IBS) significant trends, drivers, influence factors in global and regions.
6. To analyze Irritable Bowel Syndrome (IBS) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome (IBS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome (IBS) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome (IBS).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Irritable Bowel Syndrome (IBS) industry.
Chapter 3: Detailed analysis of Irritable Bowel Syndrome (IBS) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Irritable Bowel Syndrome (IBS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Irritable Bowel Syndrome (IBS) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Chapter 9: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Irritable Bowel Syndrome (IBS) Market Size, 2019 VS 2023 VS 2030
1.3 Global Irritable Bowel Syndrome (IBS) Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 IRRITABLE BOWEL SYNDROME (IBS) MARKET DYNAMICS
2.1 Irritable Bowel Syndrome (IBS) Industry Trends
2.2 Irritable Bowel Syndrome (IBS) Industry Drivers
2.3 Irritable Bowel Syndrome (IBS) Industry Opportunities and Challenges
2.4 Irritable Bowel Syndrome (IBS) Industry Restraints
3 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY COMPANY
3.1 Global Irritable Bowel Syndrome (IBS) Company Revenue Ranking in 2023
3.2 Global Irritable Bowel Syndrome (IBS) Revenue by Company (2019-2024)
3.3 Global Irritable Bowel Syndrome (IBS) Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Irritable Bowel Syndrome (IBS) Company Manufacturing Base & Headquarters
3.5 Global Irritable Bowel Syndrome (IBS) Company, Product Type & Application
3.6 Global Irritable Bowel Syndrome (IBS) Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Irritable Bowel Syndrome (IBS) Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Irritable Bowel Syndrome (IBS) Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY TYPE
4.1 Irritable Bowel Syndrome (IBS) Type Introduction
4.1.1 IBS-D Drug
4.1.2 IBS-C Drug
4.1.3 Others
4.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Type
4.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2019-2030)
4.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type (2019-2030)
5 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY APPLICATION
5.1 Irritable Bowel Syndrome (IBS) Application Introduction
5.1.1 Women
5.1.2 Men
5.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Application
5.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2019-2030)
5.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application (2019-2030)
6 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY REGION
6.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2019-2030)
6.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region: 2019-2024
6.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.3.2 North America Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.4.2 Europe Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.5.2 Asia-Pacific Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.6.2 Latin America Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.7.2 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
7 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY COUNTRY
7.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2019-2030)
7.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2019-2024)
7.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.3.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.4.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.5.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.6.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.7.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.8.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.9.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.10.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.11.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.12.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.13.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.14.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.15.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.16.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.17.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.18.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.19.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.20.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.21.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Bausch Health
8.1.1 Bausch Health Comapny Information
8.1.2 Bausch Health Business Overview
8.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Product Portfolio
8.1.5 Bausch Health Recent Developments
8.2 Allergan
8.2.1 Allergan Comapny Information
8.2.2 Allergan Business Overview
8.2.3 Allergan Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.2.4 Allergan Irritable Bowel Syndrome (IBS) Product Portfolio
8.2.5 Allergan Recent Developments
8.3 Takeda
8.3.1 Takeda Comapny Information
8.3.2 Takeda Business Overview
8.3.3 Takeda Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.3.4 Takeda Irritable Bowel Syndrome (IBS) Product Portfolio
8.3.5 Takeda Recent Developments
8.4 Sucampo Pharmaceuticals (Mallinckrodt)
8.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Comapny Information
8.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Business Overview
8.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Portfolio
8.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
8.5 Sebela Pharmaceuticals Inc
8.5.1 Sebela Pharmaceuticals Inc Comapny Information
8.5.2 Sebela Pharmaceuticals Inc Business Overview
8.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Portfolio
8.5.5 Sebela Pharmaceuticals Inc Recent Developments
8.6 Astellas Pharmaceuticals
8.6.1 Astellas Pharmaceuticals Comapny Information
8.6.2 Astellas Pharmaceuticals Business Overview
8.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio
8.6.5 Astellas Pharmaceuticals Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
10.6 Disclaimer
1.1 Product Definition
1.2 Global Irritable Bowel Syndrome (IBS) Market Size, 2019 VS 2023 VS 2030
1.3 Global Irritable Bowel Syndrome (IBS) Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 IRRITABLE BOWEL SYNDROME (IBS) MARKET DYNAMICS
2.1 Irritable Bowel Syndrome (IBS) Industry Trends
2.2 Irritable Bowel Syndrome (IBS) Industry Drivers
2.3 Irritable Bowel Syndrome (IBS) Industry Opportunities and Challenges
2.4 Irritable Bowel Syndrome (IBS) Industry Restraints
3 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY COMPANY
3.1 Global Irritable Bowel Syndrome (IBS) Company Revenue Ranking in 2023
3.2 Global Irritable Bowel Syndrome (IBS) Revenue by Company (2019-2024)
3.3 Global Irritable Bowel Syndrome (IBS) Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Irritable Bowel Syndrome (IBS) Company Manufacturing Base & Headquarters
3.5 Global Irritable Bowel Syndrome (IBS) Company, Product Type & Application
3.6 Global Irritable Bowel Syndrome (IBS) Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Irritable Bowel Syndrome (IBS) Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Irritable Bowel Syndrome (IBS) Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY TYPE
4.1 Irritable Bowel Syndrome (IBS) Type Introduction
4.1.1 IBS-D Drug
4.1.2 IBS-C Drug
4.1.3 Others
4.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Type
4.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Type (2019-2030)
4.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type (2019-2030)
5 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY APPLICATION
5.1 Irritable Bowel Syndrome (IBS) Application Introduction
5.1.1 Women
5.1.2 Men
5.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Application
5.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Application (2019-2030)
5.2.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application (2019-2030)
6 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY REGION
6.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2019-2030)
6.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Region: 2019-2024
6.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.3.2 North America Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.4.2 Europe Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.5.2 Asia-Pacific Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.6.2 Latin America Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value (2019-2030)
6.7.2 Middle East & Africa Irritable Bowel Syndrome (IBS) Sales Value Share by Country, 2023 VS 2030
7 IRRITABLE BOWEL SYNDROME (IBS) MARKET BY COUNTRY
7.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2019-2030)
7.2.1 Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2019-2024)
7.2.2 Global Irritable Bowel Syndrome (IBS) Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.3.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.4.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.5.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.6.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.7.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.8.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.9.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.10.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.11.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.12.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.13.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.14.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.15.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.16.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.17.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.18.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.19.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.20.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Irritable Bowel Syndrome (IBS) Sales Value Growth Rate (2019-2030)
7.21.2 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Irritable Bowel Syndrome (IBS) Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Bausch Health
8.1.1 Bausch Health Comapny Information
8.1.2 Bausch Health Business Overview
8.1.3 Bausch Health Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.1.4 Bausch Health Irritable Bowel Syndrome (IBS) Product Portfolio
8.1.5 Bausch Health Recent Developments
8.2 Allergan
8.2.1 Allergan Comapny Information
8.2.2 Allergan Business Overview
8.2.3 Allergan Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.2.4 Allergan Irritable Bowel Syndrome (IBS) Product Portfolio
8.2.5 Allergan Recent Developments
8.3 Takeda
8.3.1 Takeda Comapny Information
8.3.2 Takeda Business Overview
8.3.3 Takeda Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.3.4 Takeda Irritable Bowel Syndrome (IBS) Product Portfolio
8.3.5 Takeda Recent Developments
8.4 Sucampo Pharmaceuticals (Mallinckrodt)
8.4.1 Sucampo Pharmaceuticals (Mallinckrodt) Comapny Information
8.4.2 Sucampo Pharmaceuticals (Mallinckrodt) Business Overview
8.4.3 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.4.4 Sucampo Pharmaceuticals (Mallinckrodt) Irritable Bowel Syndrome (IBS) Product Portfolio
8.4.5 Sucampo Pharmaceuticals (Mallinckrodt) Recent Developments
8.5 Sebela Pharmaceuticals Inc
8.5.1 Sebela Pharmaceuticals Inc Comapny Information
8.5.2 Sebela Pharmaceuticals Inc Business Overview
8.5.3 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.5.4 Sebela Pharmaceuticals Inc Irritable Bowel Syndrome (IBS) Product Portfolio
8.5.5 Sebela Pharmaceuticals Inc Recent Developments
8.6 Astellas Pharmaceuticals
8.6.1 Astellas Pharmaceuticals Comapny Information
8.6.2 Astellas Pharmaceuticals Business Overview
8.6.3 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Revenue and Gross Margin (2019-2024)
8.6.4 Astellas Pharmaceuticals Irritable Bowel Syndrome (IBS) Product Portfolio
8.6.5 Astellas Pharmaceuticals Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
10.6 Disclaimer
